BCM
SANA icon

Bayesian Capital Management’s Sana Biotechnology SANA Stock Holding History

Bayesian Capital Management’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,424
Closed -$144K – 1041
2022
Q1 		$144K Buy
+17,424
New +$141K 0.02% 677

Other funds holding SANA

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Public Sector Pension Investment Board (PSP Investments)
Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $38.7B AUM 44.46% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bayesian Capital Management's SANA Position: Q2 2022 in Review

Bayesian Capital Management sold out of Sana Biotechnology (SANA) in Q2 2022, closing a stake of 17,424 shares — an estimated $144K sold.

Bayesian Capital Management first reported a position in SANA in Q1 2022 and held it in 1 quarter. The position peaked at $144K in Q1 2022. 116 funds tracked by Wall St. Rank hold SANA as of Q2 2022.

  • Bayesian Capital Management reported no remaining Sana Biotechnology position as of Q2 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 17,424 Sana Biotechnology shares in Q2 2022, an estimated $144K.
  • Bayesian Capital Management first reported a position in Sana Biotechnology in Q1 2022 and held it in 1 quarter.
  • Bayesian Capital Management's Sana Biotechnology position peaked at $144K in Q1 2022.
  • 116 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2022.

Based on Bayesian Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.